MedTrace Logo

DAIR for Infected Total Hip Arthroplasty - Does the Operative Approach Influence the Functional Result?

NCT03161990 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 226

Last updated 2019-06-18

No results posted yet for this study

Summary

The functional outcome and quality of life after treatment for an infected hip arthroplasty have been found to be significantly worse compared to an uncomplicated arthroplasty. However, the type of revision surgery chosen to treat the infection plays a role for the functional outcome. The concept of DAIR (debridement, antibiotics and implant retention) has been shown to yield god results with respect to infection control in cases of early infection with a stable implant and better functional results than a to-stage revision. In patients where infection control was achieved after just one DAIR procedure the functional outcome was comparable to an uncomplicated primary arthroplasty. However, it is not known if the operative approach used for the primary and revision surgery plays a role for the functional result after treatment of an infected total hip arthroplasty with DAIR. The project's aim is to investigate if the choice of the operative approach (transgluteal or posterior) for the primary hip replacement and the revision surgery has an influence on the functional result after debridement and implant retention for an infected total hip replacement.

Conditions

  • Hip Prosthesis Infection
  • Arthroplasty Complications

Interventions

PROCEDURE

Transgluteal approach to the hip joint

Operative approach to the hip joint where the abductors are partly detached from the greater trochanter and the hip joint is approached through the anterior part of the capsule.

PROCEDURE

Posterior approach to the hip joint

Operative approach to the hip joint where the short external rotators are detached from the greater trochanter and the hip joint is approached through the posterior part of the capsule.

Sponsors & Collaborators

  • Haukeland University Hospital

    collaborator OTHER

  • University Hospital, Akershus

    lead OTHER

Principal Investigators

  • Asbjorn Aaroen, Professor · University Hospital, Akershus

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-23
Primary Completion
2018-11-17
Completion
2018-11-17

Countries

  • Norway

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03161990 on ClinicalTrials.gov